Want to see BIAF full AI Analyst Report?
bioAffinity Technologies, Inc. (BIAF) AI Stock Analysis
Top Page
bioAffinity Technologies, Inc.
(NASDAQ:BIAF)
The score is held down primarily by very weak financial performance (large operating losses, margin deterioration, and substantial negative operating/free cash flow) and bearish technicals (well below key moving averages with negative MACD). Corporate events are supportive (patents, adoption momentum, Nasdaq compliance, and financing), but they do not fully offset the current loss-making and cash-burn profile; valuation is also difficult to rely on due to negative earnings and no dividend yield provided.
bioAffinity Technologies, Inc. (BIAF) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $18.28M
- Dividend Yield
- ―
- Average Volume (3M)
- 3.69M
- Price to Earnings (P/E)
- -0.0
- Beta (1Y)
- -4.56
- Revenue Growth
- -23.17%
- EPS Growth
- 67.18%
- Country
- US
- Employees
- 57
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Diagnostics & Research
bioAffinity Technologies, Inc. Business Overview & Revenue Model
Company Description
As a biotechnology enterprise, bioAffinity Technologies, Inc. is dedicated to pioneering both non-invasive diagnostic solutions and precision therapeutics for cancer. Its portfolio features CyPath lung, a specialized diagnostic test designed for the...
How the Company Makes Money
bioAffinity Technologies primarily makes money by selling its diagnostic testing products and associated laboratory services, with revenue generated when CyPath® Lung tests are ordered and performed for patients. Earnings are driven by test volume an...
bioAffinity Technologies, Inc. Financial Statement Overview
Summary
Financials are dominated by heavy losses and cash burn. Income statement quality is very weak (gross margin compressed to ~17% and EBIT/net margins deeply negative), and cash flow is a major red flag with operating/free cash flow around -$11.5M TTM, implying continued reliance on external funding. The balance sheet is not highly levered (debt-to-equity ~0.38) but is weakening as losses erode equity and assets.
Income Statement
18Very NegativeBalance Sheet
46NeutralCash Flow
20Very Negative| Breakdown | TTM | Dec 2025 | Mar 2025 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.90M | 6.16M | 9.36M | 2.53M | 4,803 | 0 |
| Gross Profit | -2.33M | 1.43M | 3.38M | 791.62K | 4,336 | -4,817 |
| EBITDA | -14.72M | -14.32M | -8.33M | -7.63M | -5.61M | -5.32M |
| Net Income | -15.19M | -14.91M | -9.04M | -7.94M | -8.15M | -6.33M |
Balance Sheet | ||||||
| Total Assets | 7.62M | 10.96M | 6.51M | 8.22M | 12.18M | 1.45M |
| Cash, Cash Equivalents and Short-Term Investments | 2.43M | 6.45M | 1.11M | 2.82M | 11.41M | 1.36M |
| Total Debt | 1.44M | 1.16M | 1.50M | 1.58M | 251.75K | 11.36M |
| Total Liabilities | 3.85M | 3.68M | 3.91M | 3.37M | 1.14M | 17.24M |
| Stockholders Equity | 3.77M | 7.28M | 2.60M | 4.86M | 11.04M | -15.79M |
Cash Flow | ||||||
| Free Cash Flow | -11.50M | -9.39M | -7.34M | -6.06M | -4.29M | -2.05M |
| Operating Cash Flow | -11.47M | -9.33M | -7.26M | -6.04M | -4.07M | -2.05M |
| Investing Cash Flow | -91.99K | -60.57K | -79.08K | -2.21M | -219.99K | 0 |
| Financing Cash Flow | 13.19M | 14.73M | 5.63M | -344.98K | 14.34M | 3.33M |
bioAffinity Technologies, Inc. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BIAF, the sentiment is Negative. The current price of 2.91 is below the 20-day moving average (MA) of 3.96, below the 50-day MA of 6.15, and below the 200-day MA of 19.25, indicating a bearish trend. The MACD of -1.03 indicates Negative momentum. The RSI at 34.00 is Neutral, neither overbought nor oversold. The STOCH value of 31.36 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BIAF.
bioAffinity Technologies, Inc. Risk Analysis
bioAffinity Technologies, Inc. disclosed 77 risk factors in its most recent earnings report. bioAffinity Technologies, Inc. reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
1 New RiskbioAffinity Technologies, Inc. Peers Comparison
Overall Rating
INBS45Neutral- BIAF43Neutral
ISPC41Neutral
NDRA34Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| INBS | 45Neutral | $5.84M | -0.19 | -170.36% | ― | 38.09% | 54.22% |
| BIAF | 43Neutral | $3.73M | -0.02 | -257.27% | ― | -23.17% | 67.18% |
| ISPC | 41Neutral | $2.08M | -0.02 | -524.37% | ― | -92.11% | 86.78% |
| NDRA | 34Underperform | $7.12M | -0.75 | -224.80% | ― | ― | 98.17% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| BIAF | bioAffinity Technologies, Inc. | 2.91 | -31.59 | -91.57% | |
| NDRA | Endra Life Sciences | 4.75 | -0.42 | -8.12% | |
| INBS | Intelligent Bio Solutions Inc. | 1.76 | -7.52 | -81.03% | |
| ISPC | Ispecimen Inc | 0.82 | -29.16 | -97.25% | |
| BGLC | Bionexus Gene Lab Corporation | 0.92 | -4.56 | -83.27% |
bioAffinity Technologies, Inc. Corporate Events
bioAffinity Showcases CyPath Lung at Awareness Event
PositiveOn October 29, 2026, bioAffinity Technologies announced it will participate in the Lung Cancer Initiative of North Carolina’s Battle of the Blues event on November 5, 2026, during National Lung Cancer Awareness Month, joining physicians, patien...
bioAffinity highlights CyPath Lung at CHEST 2026
PositiveOn October 15, 2026, bioAffinity Technologies said it will sponsor a Learning Theater session at CHEST 2026, the annual meeting of the American College of Chest Physicians, to highlight CyPath Lung’s role in lung cancer risk stratification and...
bioAffinity to Present New Sputum-Based Lung Biomarker Data
PositiveOn October 13, 2026, bioAffinity Technologies announced it will present new research data at CHEST 2026 on investigational sputum-based tests designed to characterize lung inflammation and detect multiple protein biomarkers, including targets of biol...
bioAffinity Technologies Completes New $4 Million Financing
PositiveOn October 8, 2026, bioAffinity Technologies entered into a securities purchase agreement with an institutional investor for a registered direct offering of common stock and pre-funded warrants, alongside a concurrent private placement of additional...
bioAffinity Secures Japanese Patent for CyPath Lung
PositiveOn October 8, 2026, bioAffinity Technologies announced that the Japan Patent Office issued a Notice of Allowance for a patent covering its CyPath Lung test method, which predicts the likelihood of lung cancer using automated flow cytometry and machin...
bioAffinity reports surging adoption of CyPath Lung test
PositiveOn October 6, 2026, bioAffinity Technologies reported that sales of its CyPath Lung test more than doubled through the third quarter of 2026 compared with the same period in 2025, driven by growing clinical adoption among high-risk lung cancer patien...
bioAffinity expands CyPath Lung access for U.S. veterans
PositivebioAffinity Technologies, Inc., a biotechnology firm developing noninvasive lung disease diagnostics, is centering its commercial strategy on CyPath Lung, an AI-enhanced sputum-based test for early lung cancer detection marketed as a laboratory devel...
bioAffinity to Highlight CyPath Lung at NAVREF 2026
PositiveOn September 22, 2026, bioAffinity Technologies announced it would present two posters on its CyPath Lung diagnostic at the NAVREF 2026 Annual Conference, held September 27-30, 2026, in Arlington, Virginia. The meeting convenes leaders from the Depar...
bioAffinity secures Hong Kong patent for CyPath Lung
PositiveOn September 17, 2026, bioAffinity Technologies announced that Hong Kong’s Intellectual Property Department granted a patent covering its CyPath Lung platform, which predicts the likelihood of lung cancer by using defined antibodies, the porphy...
bioAffinity Technologies Highlights Investor Presentation at Conference
NeutralbioAffinity Technologies prepared a set of presentation materials that its management plans to use in periodic discussions of the company’s operations and performance. These materials are scheduled to be presented at the H.C. Wainwright 28th An...
bioAffinity Regains Nasdaq Compliance, Maintains Capital Market Listing
PositiveOn September 9, 2026, bioAffinity Technologies announced that Nasdaq had confirmed the company regained compliance with the exchange’s minimum bid price and rights/warrants listing rules as of September 8, 2026. The decision cancels a previousl...
bioAffinity Technologies to Present Corporate Update at Conference
PositiveOn September 3, 2026, bioAffinity Technologies announced that President and CEO Maria Zannes will deliver a corporate update and conduct one-on-one investor meetings at the H.C. Wainwright 28th Annual Global Investment Conference, scheduled for Septe...
bioAffinity advances CyPath Lung for post-treatment surveillance
PositiveOn September 1, 2026, bioAffinity Technologies announced that it is advancing the potential use of its noninvasive CyPath Lung test for surveillance of lung cancer patients who have completed curative-intent treatment. The move targets a growing surv...
bioAffinity Technologies Implements Reverse Stock Split for Nasdaq
NeutralOn April 30, 2026, bioAffinity Technologies’ shareholders approved an amendment to authorize a reverse split of the company’s common stock, enabling the board to set a ratio between 1-for-2 and 1-for-250. The board subsequently selected a...
bioAffinity Technologies expands CyPath Lung federal distribution
PositiveOn August 18, 2026, bioAffinity Technologies, Inc. announced a nationwide distribution agreement with AvMEDICAL, a Service-Disabled Veteran-Owned Small Business and established supplier of medical and laboratory products to U.S. government healthcare...
bioAffinity Technologies Completes $4 Million Private Placement Financing
PositiveOn August 12, 2026, bioAffinity Technologies entered into a securities purchase agreement with an institutional investor for a private placement of pre-funded warrants and Series A and B warrants tied to 8,462,027 shares of common stock, each warrant...
bioAffinity Technologies Faces Nasdaq Delisting Risk After Notice
NegativeOn July 30, 2026, bioAffinity Technologies received notice from Nasdaq that its shares had closed below $1.00 for 30 consecutive trading days from June 16 through July 29, 2026, putting the company out of compliance with Nasdaq’s minimum bid pr...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 29, 2026